GliaGenesis aus Düsseldorf | Biotechnology | Healthcare

"AI-accelerated research to define aging in the brain, enabling personalized therapies and faster market delivery for aging populations"

Achievements

Team

Prototype

Users

Partners

Revenue

Investors

What we offer

- New biomarkers and therapeutics for aging and psychiatric disorders.
- Diagnostics and drug candidates targeting glial cells.
- AI-powered research for personalized aging therapies.
- Strategic partnerships and IP licensing to the pharmaceutical industry.
- Diagnostic pipeline for stratifying aging and predicting clinical outcomes.

Target group

- Pharmaceutical companies
- Clinical research organizations
- Healthcare providers specializing in aging and neurodegenerative diseases
- Investors in biotech and AI-driven medical solutions
- Collaborative research partners in the medical and biotech fields

Challenges

- Securing funding and investment.
- Building and maintaining strategic partnerships.
- Regulatory approvals for new diagnostics and therapeutics.
- Scaling operations efficiently.
- Protecting intellectual property and managing legal issues.

Our Story

I have been working in this area for nearly 15 years first in Academia before moving over to companies. I have seen the major gaps arise in the technologies we need to characterize aging in the brain since several years now and this is where I see an opportunity.